ISOPP CAPhO 2025 Symposium: Therapeutic Drug Monitoring of Asparaginase in Leukemia: A Review of Various Formulations

This presentation will offer an overview of the significance of serum asparaginase activity monitoring. It will provide a review of consensus recommendations for monitoring serum asparaginase activity as well as literature highlighting the variability in therapeutic drug monitoring practices. Additionally, the pharmacokinetic differences between pegaspargase and the newest pegylated formulation, calaspargase pegol, will be discussed.

Learning objectives

• Recognize the importance and identify reasons for therapeutic drug monitoring of different asparaginase formulations
• Describe the consensus recommendations for monitoring serum asparaginase activity (SAA)
• Analyze and compare differences in the pharmacokinetic profile and rates of adverse effects of pegaspargase and calaspargase pegol